Assignee
CAMURUS AB
SE·23 granted patents·34 pending applications·102 citations·filing 1987–2025
Top patents by PatentIndex Score
57 records- 0196US11135215B2Opioid formulationsCAMURUS AB·Filed 2021·Granted Oct 5, 2021·3 cites·30 claims
- 0296US10912772B2Opioid formulationsCAMURUS AB·Filed 2020·Granted Feb 9, 2021·4 cites·16 claims
- 0395US11135264B2Formulations containing a somatostatin receptor agonistCAMURUS AB·Filed 2020·Granted Oct 5, 2021·3 cites·32 claims
- 0494US12161640B2Opioid formulationsCAMURUS AB·Filed 2023·Granted Dec 10, 2024·1 cites·10 claims
- 0594US11110084B2Opioid formulationsCAMURUS AB·Filed 2021·Granted Sep 7, 2021·2 cites·30 claims
- 0694US10688148B2Formulations containing a somatostatin receptor agonistCAMURUS AB·Filed 2019·Granted Jun 23, 2020·7 cites·49 claims
- 0791US9585959B2Robust controlled-release formulationsCAMURUS AB·Filed 2012·Granted Mar 7, 2017·16 cites·34 claims
- 0891US2025281407A1Lipid depot formulationsCAMURUS AB·Filed 2024·Application pending·0 cites
- 0990US11564968B2Formulations containing a somatostatin receptor agonistCAMURUS AB·Filed 2021·Granted Jan 31, 2023·1 cites·31 claims
- 1090US9526788B2Pharmaceutical lipid compositionsCAMURUS AB·Filed 2015·Granted Dec 27, 2016·8 cites·25 claims
- 1188US12029813B2Injectable buprenorphine formulationCAMURUS AB·Filed 2021·Granted Jul 9, 2024·1 cites·22 claims
- 1287US12396944B2Injectable buprenorphine formulationCAMURUS AB·Filed 2024·Granted Aug 26, 2025·0 cites·20 claims
- 1387US12318379B2Opioid formulationsCAMURUS AB·Filed 2024·Granted Jun 3, 2025·0 cites·10 claims
- 1487US9937164B2Opioid formulationsCAMURUS AB·Filed 2013·Granted Apr 10, 2018·7 cites·28 claims
- 1586US9649382B2Topical bioadhesive formulationsCAMURUS AB·Filed 2013·Granted May 16, 2017·5 cites·23 claims
- 1686US2025000982A1Peptide slow-release formulationsCAMURUS AB·Filed 2024·Application pending·0 cites
- 1785US11241476B2Mixtures and formulations comprising an alkyl ammonium EDTA saltCAMURUS AB·Filed 2017·Granted Feb 8, 2022·1 cites·24 claims
- 1883US9968680B2Topical bioadhesive formulationsCAMURUS AB·Filed 2014·Granted May 15, 2018·5 cites·29 claims
- 1983US9555118B2Robust controlled-release peptide formulationsCAMURUS AB·Filed 2012·Granted Jan 31, 2017·5 cites·36 claims
- 2082US2023027339A1Lipid depot formulationsCAMURUS AB·Filed 2022·Application pending·0 cites
- 2181US2025319097A1Prostacyclin analogue formulationsCAMURUS AB·Filed 2024·Application pending·0 cites
- 2281US2025121035A1Controlled release peptide formulationsCAMURUS AB·Filed 2024·Application pending·0 cites
- 2380US12257282B2Mixtures and formulationsCAMURUS AB·Filed 2022·Granted Mar 25, 2025·0 cites·38 claims
- 2479US11672843B2Somatostatin receptor agonist formulationsCAMURUS AB·Filed 2013·Granted Jun 13, 2023·1 cites·29 claims
- 2577US2023372436A1Somatostatin receptor agonist formulationsCAMURUS AB·Filed 2023·Application pending·0 cites
- 2676US2026097031A1Opioid formulationsCAMURUS AB·Filed 2025·Application pending·0 cites
- 2776US2025345385A1Mixtures and formulations comprising an alkyl ammonium edta saltCAMURUS AB·Filed 2025·Application pending·0 cites
- 2874US2021128473A1Lipid depot formulationsCAMURUS AB·Filed 2020·Application pending·0 cites
- 2973US2021268112A1Peptide slow-release formulationsCAMURUS AB·Filed 2021·Application pending·0 cites
- 3073US2022387445A1Prostacyclin analogue formulationsCAMURUS AB·Filed 2022·Application pending·0 cites
- 3169US2021308226A1Controlled release peptide formulationsCAMURUS AB·Filed 2021·Application pending·0 cites
- 3268US2018311163A1Lipid depot formulationsCAMURUS AB·Filed 2018·Application pending·0 cites
- 3367US2026000730A1Somatostatin receptor agonist formulationsCAMURUS AB·Filed 2025·Application pending·0 cites
- 3467US2015064118A1Lipid depot formulationsCAMURUS AB·Filed 2014·Application pending·0 cites
- 3566US11369617B2Prostacyclin analogue formulationsCAMURUS AB·Filed 2017·Granted Jun 28, 2022·0 cites·31 claims
- 3666US2019350841A1Lipid formulations comprising a thiolated antioxidantCAMURUS AB·Filed 2018·Application pending·0 cites
- 3764US2014193347A1Lipid depot formulationsCAMURUS AB·Filed 2013·Application pending·0 cites
- 3863US2023285502A1Mixtures and formulationsCAMURUS AB·Filed 2023·Application pending·0 cites
- 3962US2019054177A1Peptide slow-release formulationsCAMURUS AB·Filed 2018·Application pending·0 cites
- 4061US5260282ASaliva substituteCAMURUS AB·Filed 1992·Granted Nov 9, 1993·16 cites·25 claims
- 4161US2018250286A1Opioid formulationsCAMURUS AB·Filed 2018·Application pending·0 cites
- 4261US2017281537A1Lipid formulations comprising a thiolated antioxidantCAMURUS AB·Filed 2017·Application pending·0 cites
- 4360US2014219935A1Topical bioadhesive formulationsCAMURUS AB·Filed 2013·Application pending·0 cites
- 4460US2018078647A1Gnrh analogue formulationsCAMURUS AB·Filed 2017·Application pending·0 cites
- 4560US2020353086A1Controlled-release formulationsCAMURUS AB·Filed 2020·Application pending·0 cites
- 4659US2013267585A1Pharmaceutical composition having a cationic excipientCAMURUS AB·Filed 2013·Application pending·0 cites
- 4758US12246055B2Lipid-controlled release compositionsCAMURUS AB·Filed 2020·Granted Mar 11, 2025·0 cites·23 claims
- 4857US2018207089A1Acid containing lipid formulationsCAMURUS AB·Filed 2017·Application pending·0 cites
- 4957US2025325626A1Lipid-controlled release compositionsCAMURUS AB·Filed 2025·Application pending·0 cites
- 5057US2025281569A1Compositions and methods for treating neuroendocrine tumorsCAMURUS AB·Filed 2022·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CAMURUS AB files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →